MEVIS MEDSOL N
MEVIS MEDSOL N operates in Diversified Metals & Mining.
MEVIS MEDSOL N (M3V) - Total Assets
Latest total assets as of March 2024: €25.13 Million EUR
Based on the latest financial reports, MEVIS MEDSOL N (M3V) holds total assets worth €25.13 Million EUR as of March 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MEVIS MEDSOL N - Total Assets Trend (2017–2023)
This chart illustrates how MEVIS MEDSOL N’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MEVIS MEDSOL N - Asset Composition Analysis
Current Asset Composition (September 2023)
MEVIS MEDSOL N's total assets of €25.13 Million consist of 40.5% current assets and 59.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.6% |
| Accounts Receivable | €2.65 Million | 9.5% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2017–2023)
This chart illustrates how MEVIS MEDSOL N's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MEVIS MEDSOL N's current assets represent 40.5% of total assets in 2023, a decrease from 68.1% in 2017.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2023, down from 60.6% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 9.5% of total assets.
MEVIS MEDSOL N Competitors by Total Assets
Key competitors of MEVIS MEDSOL N based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
2H0
F:2H0
|
Germany | €15.27 Million |
MEVIS MEDSOL N - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - MEVIS MEDSOL N generates 0.62x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, MEVIS MEDSOL N generates $ 17.54 in net profit.
MEVIS MEDSOL N - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.80 | 2.02 | 2.63 |
| Quick Ratio | 1.80 | 2.02 | 2.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.68 Million | € 3.87 Million | € 5.19 Million |
MEVIS MEDSOL N - Advanced Valuation Insights
This section examines the relationship between MEVIS MEDSOL N's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -10.1% |
| Total Assets | €28.05 Million |
| Market Capitalization | $262.75K USD |
Valuation Analysis
Below Book Valuation: The market values MEVIS MEDSOL N's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MEVIS MEDSOL N's assets decreased by 10.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MEVIS MEDSOL N (2017–2023)
The table below shows the annual total assets of MEVIS MEDSOL N from 2017 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-09-30 | €28.05 Million | -10.09% |
| 2022-09-30 | €31.20 Million | +13.32% |
| 2021-09-30 | €27.53 Million | -0.93% |
| 2020-09-30 | €27.79 Million | +16.18% |
| 2019-09-30 | €23.92 Million | -37.74% |
| 2018-09-30 | €38.42 Million | -21.72% |
| 2017-09-30 | €49.08 Million | -- |